Home » Stocks » BCEL

Atreca, Inc. (BCEL)

Stock Price: $13.85 USD -0.51 (-3.55%)
Updated Oct 28, 2020 12:21 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 499.01M
Revenue (ttm) n/a
Net Income (ttm) -76.38M
Shares Out 29.31M
EPS (ttm) -6.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $13.85
Previous Close $14.36
Change ($) -0.51
Change (%) -3.55%
Day's Open 13.94
Day's Range 13.56 - 14.03
Day's Volume 54,073
52-Week Range 9.51 - 29.35

More Stats

Market Cap 499.01M
Enterprise Value 355.52M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 29.31M
Float 27.49M
EPS (basic) -2.24
EPS (diluted) -6.36
FCF / Share -2.53
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.48M
Short Ratio 10.95
Short % of Float 12.67%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.41
Revenue n/a
Operating Income -80.85M
Net Income -76.38M
Free Cash Flow -71.07M
Net Cash 143.49M
Net Cash / Share 3.98
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -25.79%
ROE -40.96%
ROIC -148.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 7
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$29.71*
(114.51% upside)
Low
25.0
Current: $13.85
High
35.0
Target: 29.71
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-72.57-39.57-29.44
Net Income-67.48-37.94-27.53
Shares Outstanding15.832.1012.57
Earnings Per Share-4.26-18.02-2.19
Operating Cash Flow-58.54-34.70-25.10
Capital Expenditures-3.45-1.76-1.38
Free Cash Flow-61.99-36.46-26.47
Cash & Equivalents17311530.61
Total Debt0.050.100.20
Net Cash / Debt17311430.42
Assets19612236.11
Liabilities8.765.053.32
Book Value187-93.03-56.57
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Atreca, Inc.
Country United States
Employees 118
CEO John A. Orwin

Stock Information

Ticker Symbol BCEL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BCEL
IPO Date June 20, 2019

Description

Atreca, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with Merck Sharp & Dohme Corp. to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in South San Francisco, California.